Jonathan Dordick

Vice President, Strategic Alliances and Translation, Institute Professor, Departments of Chemical and Biological Engineering and Biological Sciences

Jonathan S. Dordick, Ph.D., is Institute Professor of Chemical and Biological Engineering at Rensselaer Polytechnic Institute, with joint appointments in the Departments of Biomedical Engineering and Biological Sciences.He received his B.A. degree in Biochemistry and Chemistry from Brandeis University and his Ph.D. in Biochemical Engineering from the Massachusetts Institute of Technology. At Rensselaer, he served as the Vice President for Research, the Director of the Center for Biotechnology and Interdisciplinary Studies, and Department Chair. He was the founding Co-Director of the Rensselaer-Mount Sinai Center for Engineering and Precision Medicine. Prior to joining Rensselaer, he was Professor of Chemical and Biochemical Engineering at the University of Iowa, where he also served as the founding Associate Director of the Center for Biocatalysis and Bioprocessing. He has served the biochemical engineering community as a previous chairman of the Biotechnology Division of the American Chemical Society and as an editor of Biotechnology & Bioengineering. Dr. Dordick has made foundational contributions to enzyme technology, microscale cell culture engineering, drug discovery and human toxicology, and biomanufacturing. He pioneered the development of enzymatic and chemoenzymatic methods for new materials synthesis, initiated the field of molecular bioprocessing, which combines biocatalytic molecular diversity and in vitro metabolic pathway engineering with high-throughput and high-content microfluidic- and microarray-based tools to generate biologically active compounds, and greatly expanded a fundamental understanding of enzymatic catalysis in abiotic environments critical for chemical and pharmaceutical processing. Finally, he has used biomolecular discovery and engineering to address clinical translation in areas of infectious and neurological diseases, anticoagulant therapy, and highly sensitive point-of-care biosensors based on CRISPR technology. Dr. Dordick has received numerous awards and honors, including election to the National Academy of Engineering and National Academy of Inventors, and receipt of the DIC Award for Excellence in Biochemical Engineering and James E. Bailey Award, both of the Society of Biological Engineering, Amgen Award in Biochemical and Molecular Engineering, AIChE Food, Pharmaceutical and Bioengineering Award, ACS-BIOT Marvin J. Johnson Award, ACS-BIOT Elmer Gaden Award, and International Enzyme Engineering Award. He is Fellow of the American Association for the Advancement of Science, American Chemical Society and the American Institute of Medical and Biological Engineers. Dr. Dordick has cofounded several companies, including EnzyMed, Solidus Biosciences, Inc., Redpin Therapeutics, SynAppBio, and Lavaage, Inc. He has also served on multiple White House-sponsored panels and committees in biomanufacturing. Dr. Dordick has published over 430 papers and is an inventor/co-inventor on over 50 patents and patent applications.